All Stories

Amryt - trials of AP101 now underway - broker ups target to 88p: buy at 20p or under

Tom Winnifrith
Tuesday 4 April 2017

Shares in Amryt Pharma (AMYT) are starting to move the right way and ever faster;as clear progress is made with its portfolio. On Tuesday we had the, not unexpected, news that it has started the phase 3 ( that is to say final human) trials of AP101, its lead drug candidate, a potential treatment for Epidermolysis Bullosa (EB). EB is a rare, genetic skin disorder, which causes exceptionally fragile skin

on ShareProphets | Comments
About Tom Winnifrith
Bio
Tom Winnifrith is the editor of TomWinnifrith.com. When he is not harvesting olives in Greece, he is (planning to) raise goats in Wales.
Twitter
@TomWinnifrith
Email
[email protected]
Recently Featured on ShareProphets
Sign up for my weekly newsletter








Required Reading

Recent Comments


I also read